San Diego-based Trovagene Inc., a developer of cell-free molecular diagnostics, announced the pricing of an expected $20 million underwritten public offering of 4.4 million shares of its common stock.

The offering is expected to close about Feb. 11 and is subject to customary closing conditions. Trovagene has also granted to the underwriters a 30-day option to purchase an additional 666,666 shares of its common stock.

Trovagene intends to use the net proceeds from this offering to fund its research and development activities and for working capital and other general corporate purposes.

Piper Jaffray & Co. is acting as sole book-running manager and Janney Montgomery Scott LLC, Maxim Group LLC and Cantor Fitzgerald & Co. are acting as co-managers for the offering.